TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership. Risk and Volatility TScan Therapeutics has a beta […]
Shares of TScan Therapeutics, Inc. (TCRX) are up 5% on Tuesday after the company announced that it received FDA clearance for its IND application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME).